CHIDINMA EZE: Open Payments
NPI 1497283097 · MILLERSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,001 in 79 payments from 10 companies in 2025. Trend: 2023 $91 · 2024 $1,698 · 2025 $2,001
Food & beverage: $2,001
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $415 |
| Neurocrine BioSciences, Inc. | 10 | $291 |
| Alkermes, Inc. | 12 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $214 |
| Otsuka America Pharmaceutical, Inc. | 9 | $201 |
| Teva Pharmaceuticals USA, Inc. | 8 | $194 |
| Lundbeck LLC | 7 | $149 |
| Janssen Pharmaceuticals, Inc | 3 | $124 |
| E.R. Squibb & Sons, L.L.C. | 5 | $104 |
| ABBVIE INC. | 2 | $52 |
Products named: FANAPT, INGREZZA, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, REXULTI, INVEGA SUSTENNA, HETLIOZ.
Industry payments across MD — which companies pay providers there.
